Increased Human Chorionic Gonadotropin Due to Hypogonadism after Treatment of a Testicular Seminoma

Lempiäinen, Anna; Hotakainen, Kristina; Blomqvist, Carl; Alfthan, Henrik; Stenman, Ulf‐Hǎkan

doi:10.1373/clinchem.2007.088518

Cited by 26 publications

(19 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another important finding is that intense chemotherapy often suppresses gonadal function, which may cause a moderate increase in serum hCG after initial normalization of the concentration ( Figure 5). This must not be interpreted as a relapse, and the condition can be identified by determination of serum LH, which is strongly elevated 108,135 .…”

Section: Functions Of Tati In Cancermentioning

confidence: 99%

Biomarker development, from bench to bedside

Stenman

2015

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Application of laser & photonics in dentistry and medicine has a long history, however, it is still emerging as a new field enabling the application of advanced technology at precise size and levels and the exploitation of novel properties. Many areas of dental/medical device are expected to benefit from photonics including sensors for use in the laboratory , the clinic, and within the human body. For example, the potential uses of laser include the early detection and treatment of disease. These new innovative biomedical pho-tonics include "advanced bioimaging" to push photon-based imaging tools to new limits of resolution and utility for "molecular and cellular imaging" to develop and apply advanced optical diagnostic probes to important problems in molecular and cellular biology, and "biomedical photon-ics" to translate photonics to clinical dentistry/medicine for disease screening, diagnosis and therapy. Launched in April 2015, the Japan Agency for Medical Research and Development （AMED） pursues its assigned mission to fast-track medical research and development in support of humanity. AMED is currently tackling the challenge of reforming Japan＇s funding allocation and evaluation systems. Other significant tasks in fast-tracking the social implementation of research outcomes include rapid diagnosis of undiagnosed diseases, and novel therapeutic interventions for patients. AMED engages in research and development in the field of medicine, establishing and maintaining an environment for this R&D, and providing funding, in order to promote integrated medical R&D from basic research to practical applications, to smoothly achieve application of outcomes, and to achieve comprehensive and effective establishment / maintenance of an environment for medical R&D. Providing a one-stop service for research expenses, AMED consolidates budgets for research expenses, which had previously been allocated from different sources-the Ministry of Education, Culture, Sports, Science and Technology , the Ministry of Health, Labour and Welfare, and the Ministry of Economy, Trade and Industry. AMED aims to achieve the world＇s highest level of medical care / service and to form a society in which people live long, healthy lives by promoting integrated research and development, from basic research to practical application, and by establishing and maintaining an environment therefor, and linking this to various forms of growth in medical R&D. In this special lecture I would introduce a birds-eye view not only AMED supporting R&D program but also FMDIPA activity to develop dental/medical laser device industry, currently being undertaken to overcome the problems facing dental/medical diseases. He has made extensive contributions to the development of the bioengineering profession worldwide through his extensive professional activities and service with the government. He has also extensive experience in working with industry partners. In recognition of his contribution and leadership, he was elected for the initiative member to start up t...

show abstract

Section: Functions Of Tati In Cancermentioning

confidence: 99%

Biomarker development, from bench to bedside

Stenman

2015

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

show abstract

“…Such hypogonadism can also be spontaneous. This can be confirmed by measurement of serum luteinizing hormone and follicle-stimulating hormone and, when necessary, suppression with testosterone replacement (99 ). Therefore, hCG levels increasing from below 2 up to 5-8 U/L during chemotherapy are often iatrogenic and do not necessarily indicate relapse.…”

Section: Hcg and Hcg␤mentioning

confidence: 90%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

et al. 2008

Self Cite

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed. Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.

show abstract

“…This finding caused suspicion of a relapse, a diagnosis that was excluded on the basis of assay results for luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and the suppression of hCG with testosterone replacement (6 ). This case shows that increased hCG associated with hypogonadism can also occur in men.…”

Section: Hypogonadismmentioning

confidence: 93%